Objective　To observe the curative effect and sid e effect of the gastrokinetic agent mosapride citrate by RCT. Methods　 42 cases of functional dyspepsia (FD) were divided into two groups rando mly, the group of mosapride(21 cases):orally administrated mosapride, 5mg, t.i.d for 4 weeks, and the control (21 cases):orally administrated domperidone, 5mg, t.i.d for 4 weeks. Symptoms and side effects were recorded before and at d 14, d 28 after administration of the medicines according to GCP and double blind pri ciple. Gastric empting test was also carried out in randomly selected patients. Results　Mosapride and domperidone were significantly effective on alleviating symptoms of the patient with FD. In mosapride treated group the half emptying time was shortened and the 120 min remain rate was reduced. No sid e effect was found. Conclusion　These results suggest that mosa pride 5 mg t.i.d. is effective and safe on alleviating symptoms of patients with FD and improving the ga stric empting time.

A specific and sensitive radioimmunoprecipitation method was used to detect antibody against liver-specific membrane lipoprotein (LSP) in the sera of 182 patients with viral hepatitis, HBsAg chronic carriers and liver cirrhosis and 40 patients with other diseases as control. The results showed that the highest frequency of anti-LSP was noticed in the patients with severe hepatitis (15 out of 16 cases, 93.8%), and in the patients with chronic active hepatitis, acute viral hepatitis, chronic persistent hepatitis, cirrhosis and other diseases and in the HBsAg chronic carriers the incidences were 83.6%(41/49 cases), 66.2% (43/65), 63.6%(14/22), 55.0%(11/20), 5%(2/40) and 10%(1/10) respectively. The frequencies of anti-LSP in the patients with various types of viral hepatitis were significantly higher than those in the HBsAg chronic carriers and in the patients with other diseases (P